|
|
|
| Efficacy of metformin in the treatment of metabolic syndrome in patients with schizophrenia and its relationship with chronic inflammatory state |
| LI Meihua1, ZHU Cheng1, ZHENG Ke2, LIU Jiahong1, LYU Wei1. |
| 1.Department of General Psychiatry, Kangning Hospital Affiliated to Wenzhou Medical University,Wenzhou 325000, China; 2.Department of Behavioral Medicine, Kangning Hospital Affiliated to Wenzhou Medical University, Wenzhou 325000, China |
|
| Cite this article: |
|
LI Meihua,ZHU Cheng,ZHENG Ke, et al. Efficacy of metformin in the treatment of metabolic syndrome in patients with schizophrenia and its relationship with chronic inflammatory state[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2022, 52(5): 382-387.
|
|
|
|
Abstract Objective: To analyze the efficacy of metformin in the treatment of metabolic syndrome in patients with schizophrenia, and to further analyze the effect of the C-reactive protein (CRP) changes and tumor necrotic factor-α (TNF-α) on metabolic syndrome. Methods: According to the medical record number, 100 patients with schizophrenia who met the inclusion criteria and exclusion criteria were randomly divided into study group (n=50) and control group (n=50). Body mass index (BMI), homeostasis insulin evaluation index (HOMA-IR), fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglyceride (TG), CRP,TNF-α were measured before and 24 weeks after intervention treatment. Collected data were analyzed by SPSS.Results: There was no significant difference in sex, education, marriage, family history, course of disease, age and dose distribution of olanzapine between the study group and the control group (P>0.05). ΔBMI, ΔHOMA-IR,ΔFPG, ΔHbA1c, ΔHDL-C, ΔLDL-C, ΔTC, ΔTG, ΔCRP, ΔTNF-α in the study group was significantly higher than those in the control group after intervention (P<0.05). ΔCRP and ΔTNF-α in the study group had significantly positive correlation with ΔBMI and ΔHOMA-IR. ΔCRP could explain 13.4% of the ΔBMI variation and 11.4% of the ΔHOMA-IR variation, while 12.5% of the ΔBMI variation and 14.2% of the ΔHOMA-IR variation could be respectively explained by ΔTNF-α. Conclusion: Metformin can effectively improve the metabolic syndrome in patients with schizophrenia, while the improvement of metabolic syndrome may be related to the reduction of inflammatory state.
|
|
Received: 05 October 2021
|
| |
|
|
|
|
|
|
